Loading...
•
Mar 31, 2022
Biomea Fusion Q1 2022 Earnings Report
Reported first quarter 2022 financial results and business highlights.
Key Takeaways
Biomea Fusion reported a net loss of $16.4 million for the quarter ended March 31, 2022, and had cash, cash equivalents, restricted cash, and investments of $165.6 million as of March 31, 2022.
COVALENT-101 study continues to enroll relapsed/refractory (R/R) acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) patients and has included R/R diffuse large B-cell lymphoma (DLBCL) and R/R multiple myeloma (MM) patients to the study.
Presented preclinical validation data for BMF-219 in multiple solid and liquid tumor types at AACR 2022, with BMF-219 showing strong cytotoxic activity as a single agent.
Announced upcoming presentation of preclinical in vivo data of BMF-219 in diabetes at the American Diabetes Association (ADA) Scientific Sessions 2022 and plans to initiate a Phase I/II trial in the second half of 2022.
Cash position of $165.6 million at the end of the first quarter of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...